Subscribe to Newsletter
Subspecialties Basic & Translational Research, Retina, Retina

The MHC Matchmaker

Ophthalmic research has been at the forefront of the drive for clinical translation, and the use of human induced pluripotent stem cells (iPSCs) for the treatment of retinal disease like AMD is a striking example of this. You can take, say, a skin epithelial cell, induce pluripotency, and soon you have a self-renewing reservoir of cells that can be differentiated into almost every cell type, including RPE, which can then be implanted to try and treat disease. However, there’s a very practical problem: the high cost. The use of allogeneic – human, but genetically and immunologically dissimilar – stem cells could help reduce that cost burden; you could order RPE from an iPS cell bank. But this raises the issue of graft rejection. These cells will go on to express the wrong major histocompatibility complex (MHC) antigens, and the immune system kicks in to play.

Figure 1. The results of transplanting MHC-matched or -mismatched allografts using iPSC-derived RPE cells (iPS-RPE) established from a MHC homozygote donor (1).

Credit: Sunao Sugita.

Now, Sugita et al., (1) have, in cynomolgus monkeys, shown that you can successfully use allogeneic iPSC-derived RPE cells, without immunosuppression, so long as those iPSCs come from a MHC-matched donor (Figure 1). If the iPSCs came from a MHC-mismatched donor, as expected, the immune system was unleashed: the RPE exhibited inflammatory and hypertrophic changes, and many inflammatory cells invaded the graft area, such as Iba1+ cells, MHC class II+ cells, and CD3+ T cells. The authors concluded that “cells derived from MHC homozygous donors could be used to treat retinal diseases in histocompatible recipients.”

Where to now? The study’s lead author explained,  “In our next clinical trial, we plan to use allogeneic iPS-RPE cells from HLA homozygote [matched] donors. The clinical data after the transplantation will allow us to see if the iPS cell bank is truly useful or not. If so, I think this type of transplantation can become [the] standard treatment within five years.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. S Sugita et al., “Successful transplantation of retinal pigment epithelial Cells from MHC homozygote iPSCs in MHC-matched models”, Stem Cell Reports, [Epub ahead of print] (2016). PMID: 27641649.
About the Author
Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: